Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025

Reuters10-17

Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025

Agenus Inc. has announced new clinical data on its combination immunotherapy, botensilimab (BOT) and balstilimab $(BAL)$, at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The results, presented in an oral session, showed that approximately 39% of late-stage, refractory solid tumor patients treated with BOT/BAL were alive at two years. The study included data from 411 patients across more than five cancer types, with 61% having received three or more prior lines of therapy. Additional poster presentations at ESMO 2025 highlighted clinical activity in hard-to-treat cancers, including cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancer. The findings support ongoing and future randomized trials, such as the phase 3 BATTMAN trial, and have contributed to the authorization of BOT/BAL for compassionate use in France for patients with refractory MSS mCRC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251017753429) on October 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2576322760?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576322760","market":"nz","top_or_hot":-1,"title":"Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. has announced new clinical data on its combination immunotherapy, botensilimab (BOT) and balstilimab <a href=\"https://laohu8.com/S/BAL\">$(BAL)$</a>, at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The results, presented in an oral session, showed that approximately 39% of late-stage, refractory solid tumor patients treated with BOT/BAL were alive at two years. The study included data from 411 patients across more than five cancer types, with 61% having received three or more prior lines of therapy. Additional poster presentations at ESMO 2025 highlighted clinical activity in hard-to-treat cancers, including cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancer. The findings support ongoing and future randomized trials, such as the phase 3 BATTMAN trial, and have contributed to the authorization of BOT/BAL for compassionate use in France for patients with refractory MSS mCRC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251017753429) on October 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-17 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. has announced new clinical data on its combination immunotherapy, botensilimab (BOT) and balstilimab <a href=\"https://laohu8.com/S/BAL\">$(BAL)$</a>, at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The results, presented in an oral session, showed that approximately 39% of late-stage, refractory solid tumor patients treated with BOT/BAL were alive at two years. The study included data from 411 patients across more than five cancer types, with 61% having received three or more prior lines of therapy. Additional poster presentations at ESMO 2025 highlighted clinical activity in hard-to-treat cancers, including cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancer. The findings support ongoing and future randomized trials, such as the phase 3 BATTMAN trial, and have contributed to the authorization of BOT/BAL for compassionate use in France for patients with refractory MSS mCRC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251017753429) on October 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉纳斯公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL8nl80Z:1","article_id":"2576322760","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576322760","pubTimestamp":1760702440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus Inc. has announced new clinical data on its combination immunotherapy, botensilimab  and balstilimab , at the European Society for Medical Oncology  Congress 2025 in Berlin, Germany. The results, presented in an oral session, showed that approximately 39% of late-stage, refractory solid tumor patients treated with BOT/BAL were alive at two years. The study included data from 411 patients across more than five cancer types, with 61% having received three or more prior lines of therapy. Additional poster presentations at ESMO 2025 highlighted clinical activity in hard-to-treat cancers, including cervical cancer, MSS metastatic colorectal cancer , and non-melanoma skin cancer. The findings support ongoing and future randomized trials, such as the phase 3 BATTMAN trial, and have contributed to the authorization of BOT/BAL for compassionate use in France for patients with refractory MSS mCRC.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"Agenus在ESMO 2025上报告BOT/BAL免疫疗法治疗多种难治性实体瘤的两年生存率为39%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025\n    \n\n        Agenus Inc. has announced new clinical data on its combination immunotherapy, botensilimab (BOT) and balstilimab $(BAL)$, at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The results, presented in an oral session, showed that approximately 39% of late-stage, refractory solid tumor patients treated with BOT/BAL were alive at two years. The study included data from 411 patients across more than five cancer types, with 61% having received three or more prior lines of therapy. Additional poster presentations at ESMO 2025 highlighted clinical activity in hard-to-treat cancers, including cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancer. The findings support ongoing and future randomized trials, such as the phase 3 BATTMAN trial, and have contributed to the authorization of BOT/BAL for compassionate use in France for patients with refractory MSS mCRC.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251017753429) on October 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576322760","isCrawlerRequest":true}